Medifocus Inc V.MFS

Primary Symbol: MDFZF

Healthcare Biotechnology

Medifocus Inc develops and sells minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BHP). It owns two focused heat technology platforms, The Endo-thermotherapy Platform-from which Prolieve was developed, can be used to treat cancers in prostate, rectal, cervical and esophageal, and The Adaptive Phased Array Microwave Focusing Platform which directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The company through its operations generates revenue from the United States.

EXPM:MDFZF - Post by User

Medifocus Inc

Bullboard Posts

Post by Bullboards_Sealon Apr 11, 2014 5:07pm

192 Views

Post# 22442065

Medifocus Inc. Announces Extension of Warrants

TORONTO, ONTARIO--(Marketwired - April 11, 2014) - Medifocus Inc. (Medifocus or the Company) (TSX VENTURE:MFS)(OTCQX:MDFZF) is pleased to announce that it has received approval from the TSX Venture Exchange (the Exchange) to extend the expiry date of 2,449,997 outstanding common share purchase warrants issued pursuant to the private placement announced April 9, 2010 (the Warrants) by one year. The expiry date of the Warrants was extended to April 24, 2014 in April, 2013 after having been extended to April 24, 2013 in April, 2012. Each Warrant entitles the holder to acquire one common share of Medifocus at a price of $0.50.

The Company will extend the term of the Warrants from April 24, 2014 to April 9, 2015. All other terms and conditions of the Warrants (as amended) will remain unchanged and in full force and effect.

About Medifocus, Inc.

Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drug Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus' APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers. Please visit www.medifocusinc.com, www.prolieve.com and https://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Medifocus Contact:

John Mon, COO

Medifocus, Inc.

410-290-5734

JohnMon@medifocusinc.com

Investor Relations Contact:

Robert Giordano

Consulting for Strategic Growth 1

917-327-3938

rgiordanonyc@gmail.com

Marketwired (Canada)

April 11, 2014 - 4:21 PM EDT